IGC Pharma (IGC) EV to FCF (2010 - 2025)

IGC Pharma (IGC) has reported EV to FCF for 16 consecutive years, with 27.12 the latest figure, recorded in Q3 2025.

• On a quarterly basis, EV to FCF rose 10.82% year-over-year to 27.12 in Q3 2025; TTM through Sep 2025 was 6.61, a 6.25% decrease from a year earlier, with the FY2026 full-year figure at 21.01, down 355.34% from the prior year.
• EV to FCF was 27.12 for Q3 2025 at IGC Pharma, down from 11.69 in the prior quarter.
• Over five years, EV to FCF peaked at 5.27 in Q4 2022 and troughed at 47.09 in Q1 2024.
• A 5-year average of 20.64 and a median of 17.31 in 2024 frame the typical range for EV to FCF.
• Across the five-year window, EV to FCF tumbled 969.23% in 2021 and soared 75.62% in 2023, its largest moves.
• Over 5 years, EV to FCF stood at 15.48 in 2021, then surged by 65.93% to 5.27 in 2022, then tumbled by 88.71% to 9.95 in 2023, then sank by 92.9% to 19.2 in 2024, then tumbled by 41.25% to 27.12 in 2025.
• The last three EV to FCF figures came in at 27.12 (Q3 2025), 11.69 (Q2 2025), and 30.27 (Q1 2025), per Business Quant data.